Dyve is a clinical stage biotech company with its lead asset, DYV700, currently completing a 20- center, 100-patient, Phase 2 clinical study for the treatment of acute gout. Dyve’s transdermal delivery science platform overturns the traditional limitations of administering therapies. It combines the fast onset of action of an injection with the extended duration and bioavailability of an oral pill – creating ideal PK/PD parameters and an optimal drug profile. Dyve has a robust internal pipeline of novel drugs and a research collaboration in place with a Top 10 Pharmaceutical Company on a separate set of target NCEs.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
DYV-700 completing Phase 2 for the treatment of acute gout.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
up to 5